11R-VIVIT inhibits the expression of urokinase-type plasminogen activator receptor in podocytes.
- Author:
Ruizhao LI
1
;
Wei SHI
;
Juan MA
;
Bin ZHANG
;
Li ZHANG
;
Xinling LIANG
;
Yuanhan CHEN
;
Shuangxin LIU
;
Wenjian WANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Disease Models, Animal; Lipopolysaccharides; adverse effects; Male; Mice; Mice, Inbred C57BL; Oligopeptides; pharmacology; Podocytes; drug effects; metabolism; Proteinuria; drug therapy; metabolism; Receptors, Urokinase Plasminogen Activator; metabolism
- From: Journal of Southern Medical University 2013;33(7):1022-1026
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of 11R-VIVIT on lipopolysaccharide (LPS)-induced expression of urokinase-type plasminogen activator receptor (uPAR) in podocytes.
METHODSA LPS-induced proteinuria mouse model and in vitro cultured podocytes treated with LPS were both divided into control group, LPS group and LPS+11 R-VIVIT group. The mRNA and protein expressions of uPAR in mouse kidney tissues and the podocytes were measured by real-time qPCR, laser scanning confocal microscopy and Western blotting.
RESULTSCompared with LPS group, LPS+11 R-VIVIT group showed a significantly lowered urine albumin/creatinine ratio (P<0.001) and markedly reduced mRNA and protein expressions of uPAR (PuPAR mRNA<0.001; PuPAR=0.001).
CONCLUSION11R-VIVIT can ameliorate proteinuria probably by decreasing the expression of uPAR in podocytes.
